TuisABVX • EPA
add
Abivax SA
Vorige sluiting
€6,47
Jaarwisseling
€6,32 - €15,42
Markkapitalisasie
409,86 m EUR
Gemiddelde volume
24,98 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
EPA
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 3,39 m | 201,87% |
Bedryfskoste | 43,39 m | 119,55% |
Netto inkomste | -40,82 m | -57,14% |
Netto winsgrens | -1,20 k | 47,94% |
Wins per aandeel | — | — |
EBITDA | -39,91 m | -114,56% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 222,32 m | 94,37% |
Totale bates | 284,49 m | 66,29% |
Totale aanspreeklikheid | 158,02 m | 74,43% |
Totale ekwiteit | 126,47 m | — |
Uitstaande aandele | 62,92 m | — |
Prys om te bespreek | 3,22 | — |
Opbrengs op bates | -35,15% | — |
Opbrengs op kapitaal | -41,69% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -40,82 m | -57,14% |
Kontant van bedrywe | -42,59 m | -208,62% |
Kontant van beleggings | 6,73 m | 886,10% |
Kontant van finansiering | 20,16 m | -65,46% |
Netto kontantverandering | -14,81 m | -133,88% |
Beskikbare kontantvloei | -21,07 m | -45,88% |
Meer oor
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Gestig
04 Des. 2013
Webwerf
Werknemers
62
